Same active ingredient. Not the same product.
Same
- Active ingredient (semaglutide or tirzepatide molecule)
- Mechanism, dosing range, clinical effects
- Side effect profile
Different
- FDA approval. Branded is approved finished drug. Compounded is prepared under 503A/503B federal exceptions — not FDA-approved as finished products.
- Manufacturing. Branded: cGMP. 503B: cGMP. 503A: USP standards, not cGMP.
- Concentration / excipients / device. Vary.
- Pricing. Branded $1,000+/mo list. Compounded $145–$269/mo cash-pay.
- Regulatory stability. Compounded supply subject to FDA shortage rules and state board oversight.
Prefer branded when
- Insurance covers it
- Need indication-specific approved label (Wegovy CV, Zepbound OSA)
- Prefer calibrated pen injector
Compounded reasonable when
- Cash-pay (no coverage, high deductible, excluded)
- Comfortable with 503A/503B framework
- Accept that finished product isn't FDA-approved
Evaluating a compounded provider
- Are pharmacy partners named?
- Is 503A or 503B classification disclosed?
- What standards (USP <797>, <85>) are referenced?
- Third-party batch testing for 503B?
- Clinical oversight clearly described?
Strong example: NexLife discloses six partners across 503A and 503B.